Related Experiment Video
Updated: Sep 3, 2025
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]
1Department of Neonatology, Xiamen Maternal and Child Health Care Hospital, Xiamen, Fujian 361001, China.
Insights
Genetic factors, specifically single nucleotide polymorphisms, influence caffeine treatment effectiveness for apnea of prematurity (AOP) in preterm infants. Understanding these gene variations can guide personalized AOP therapy.
Area of Science:
- Neonatal Medicine
- Pharmacogenetics
- Respiratory Physiology
Background:
- Apnea of prematurity (AOP) is a common condition in preterm infants, stemming from immature respiratory control.
- Untreated AOP can lead to severe outcomes, including respiratory failure and hypoxic brain injury.
- Caffeine is a primary treatment for AOP, but its efficacy is variable among infants.
Purpose of the Study:
- To review gene polymorphisms impacting caffeine efficacy in AOP treatment.
- To highlight the role of genetic factors in AOP pathogenesis and response to therapy.
- To provide a foundation for individualized caffeine therapy strategies.
Main Methods:
- Literature review of studies on gene polymorphisms and caffeine efficacy in AOP.
- Analysis of research linking single nucleotide polymorphisms (SNPs) to treatment outcomes.
- Synthesis of current understanding of genetic influences on AOP management.
Main Results:
- Several gene polymorphisms have been identified as significantly affecting caffeine's effectiveness in preterm infants.
- Single nucleotide polymorphisms (SNPs) represent a key area of research in predicting treatment response.
- Genetic variations contribute to the observed variability in caffeine therapy outcomes.
Conclusions:
- Gene polymorphisms play a crucial role in determining individual responses to caffeine for AOP.
- Identifying relevant gene variations can facilitate personalized medicine approaches.
- Further research into pharmacogenetics is essential for optimizing AOP treatment.
Abstract:
Apnea of prematurity (AOP) is one of the common diseases in preterm infants. The main cause of AOP is immature development of the respiratory control center. If AOP is not treated timely and effectively, it will lead to respiratory failure, hypoxic brain injury, and even death in severe cases. Caffeine is the first choice for the treatment of AOP, but its effectiveness varies in preterm infants. With the deepening of AOP research, more and more genetic factors have been confirmed to play important roles in the pathogenesis and treatment of AOP; in particular, the influence of single nucleotide polymorphism on the efficacy of caffeine has become a research hotspot in recent years. This article reviews the gene polymorphisms that affect the efficacy of caffeine, in order to provide a reference for individualized caffeine therapy. Citation.
